Comparison of two different combination immunosuppressive therapies in the treatment of vogt-koyonagi-harada syndrome

Ocular Immunology and Inflammation

Volumn 21, Issue 1, 2013, Pages 47-52

  Arcinue, Cheryl A ^a,b   Radwan, Alaa ^a,b   Lebanan, May O ^c   Stephen Foster, C ^a,b,d  

^a MASSACHUSETTS EYE RESEARCH AND SURGERY INSTITUTION   (United States)

^b Massachusetts Eye Research and Surgery Institute   (United States)

^c UNIVERSITY OF THE PHILIPPINES MANILA   (Philippines)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Azathioprine; Cyclosporine; Immunosuppressive therapy; Mycophenolate mofetil; Vogt Koyonagi Harada (VKH) syndrome

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; CYCLOSPORIN; DRUG DERIVATIVE; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; MALE; REMISSION; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VOGT KOYANAGI SYNDROME; COMPARATIVE STUDY; DOSE RESPONSE; DRUG COMBINATION; IMMUNOLOGY; MENINGOENCEPHALITIS; METHODOLOGY;

ADULT; AZATHIOPRINE; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; MALE; MYCOPHENOLIC ACID; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UVEOMENINGOENCEPHALITIC SYNDROME;

MLCS; MLOWN;

EID: 84872284265     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.3109/09273948.2012.728668     Document Type: Article

References (20)

1. Agarwal M, Ganesh SK, Biswas J. Triple agent immunosuppressive therapy in Vogt-Koyanagi-Harada syndrome. Ocul Immunol Inflamm. 2006;14:333-339.
2. Paredes I, Ahmed M, Foster CS. Immunomodulatory therapy for Vogt-Koyanagi-Harada patients as first-line therapy. Ocul Immunol Inflamm. 2006;14:87-90.
3. Rao NA. Management of intraocular inflammation. In: Ryan SJ, ed. Retina, vol. 2. St. Louis, MO: Mosby; 2001:1032-1038.
4. Foster CS, Vitale AT. Immunosuppressive chemotherapy. In: Foster and Vitale. Diagnosis and Treatment of Uveitis. Philadelphia, PA: WB Saunders; 2002:177-214.
5. Cuchacovich M, Solanes F, Diaz G, et al. Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm. 2010;18:200-207.
6. Kim SJ, Yu HG. The use of low-dose azathioprine in patients with Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm. 2007;15:381-387.
7. Snyder DA, Tessler HH. Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol. 1980;90:69-75.
8. Andreoli CM, Foster CS. Vogt-Koyanagi-Harada disease. Int Ophthalmol Clin. 2006;46:111-122.
9. Rao NA. Treatment of Vogt-Koyanagi-Harada disease by corticosteroids and immunosuppressive agents. Ocul Immunol Inflamm. 2006;14:71-72.
10. Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130:492-513.
11. Andrasch RH, Burns RP. Immunosuppressive therapy in severe chronic uveitis. Arch Ophthal. 1978;96:247-251.
12. Lau CH, Comer M, Lightman S. Long-term efficacy of mycophenolate mofetil in the control of severe intraocular inflammation. Clin Exp Ophthalmol. 2003;31:487-491.
13. Wider RL. Treatment of patients with rheumatoid arthritis refractory to standard therapy. JAMA. 1988;259:2446-2449.
14. Mourad G, et al. Triple agent immunosuppression (cyclosporine, azathioprine and low dose prednisolone) an effective regimen in first cadaver kidney transplantation. Transplant Proc. 1987;19:3672-3673.
15. Hooper PL, Kaplan HJ. Triple agent immunosuppression in serpiginous choroiditis. Ophthalmology. 1991;98:944-951.
16. Nussenblatt RB, Palestine AG, Chan CC. Cyclosporine therapy for uveitis: long-term followup. J Ocul Pharmacol. 1985;1:369-382.
17. Kaçmaz RO, Kempen JH, Newcomb C, et al. Cyclosporine for ocular inflammatory diseases. Ophthalmology. 2010;117:576-584.
18. Vitale AT, Rodriguez A, Foster CS. Low dose cyclosporine A therapy in treating chronic, noninfectious uveitis. Ophthalmology. 1996;103:365-374.
19. Liu X, Yang P, Lin X, et al. Inhibitory effect of cyclosporine A and corticosteroids on the production of IFN-γ and IL-17 by T cells in Vogt-Koyonagi-Harada syndrome. Clin Immunol. 2009;131:333-342.
20. Cho ML, Ju JH, Kim KW, et al. Cyclosporine A inhibits IL-15-induced IL-17 production in CD4+ T cells via down-regulation of PI3K/Akt and NF-kappaB. Immunol Lett. 2007;108:88-96.